We see our partnership with CFFTI as an important step toward developing point of care diagnostic tests to monitor disease progression and identifying potential drug targets," said Dr.
Under the agreement, CFFTI retains exclusive rights to develop target molecules for new therapeutics for cystic fibrosis, while Proteome Systems retains exclusive rights to diagnostic and prognostic applications.